Table 3. Clinicopathological variables for 5-year disease-free, locoregional recurrence-free, distant metastasis-free, and overall survival in the univariate analysis.

Variables	Disease-free survival			Overall survival
	χ2	P value		χ2	P value
Quadrant (outer vs. upper-inner vs. lower-inner/central)	6.345	0.012		3.924	0.048
Histological grade (I vs. II vs. III)	27.8752	<0.001		57.655	<0.001
pCR (yes vs. no)	0.234	0.629		2.540	0.111
Type of surgery (MRM vs. BCS)	0.0077	0.9301		0.4431	0.5056
Clinical stage (II vs. III)	64.2814	<0.001		4.810	0.028
IMN-RT (yes vs. no)	0.616	0.433		0.0002	0.9876
Standard endocrine therapy (yes vs. no)	1.246	0.264		0.267	0.606
Luminal subtype (luminal A vs. luminal B)	7.039	0.008		13.838	<0.001
Pretreatment LMR (>5.2 vs. ≤5.2)	27.758	<0.001		16.531	<0.001
Margin (negative vs. positive)	0.0974	0.7549		0.0704	0.7908
ypN0 (yes vs. no)	1.108	0.292		4.637	0.031
PR (negative vs. positive)	0.954	0.329		2.104	0.147
RT (yes vs. no)	0.298	0.585		1.136	0.286
NAC regimen (TC vs. AT)	1.671	0.196		0.117	0.732
Pathological stage (I–II vs. III)	1.542	0.214		3.272	0.070

AT, doxorubicin docetaxel; BCS, breast-conserving surgery; IMN-RT, internal mammary node radiotherapy; LMR, lymphocyte-to-monocyte ratio; MRM, modified radical mastectomy, NAC, neoadjuvant chemotherapy; pCR, pathological complete response; PR, progesterone receptor; RT, Radiation Therapy; TC, docetaxel cyclophosphamide; ypN0, N0 after neoadjuvant chemotherapy.